Does Rallies show 13F holders for PCVX?

Yes. Rallies tracks hedge fund and 13F ownership data for PCVX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PCVX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PCVX. It does not provide personalized investment advice.

PCVX (Vaxcyte) Stock Analysis - Hedge Fund Holdings

Vaxcyte (PCVX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCVX trades at $47.17 with a market cap of $6.99B and a P/E ratio of -12.31. PCVX moved -3.28% today. Year to date, PCVX is +2.48%; over the trailing twelve months it is +28.99%. Its 52-week range spans $27.66 to $118.62. Analyst consensus is strong buy with an average price target of $109.43. Rallies surfaces PCVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PCVX stock?

Hedge funds tracked by Rallies that own PCVX include Maverick Capital, Farallon Capital, Baupost Group, Orbimed Advisors, and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vaxcyte.

PCVX Key Metrics

Key financial metrics for PCVX
Metric	Value
Price	$47.17
Market Cap	$6.99B
P/E Ratio	-12.31
EPS	$-3.80
Dividend Yield	0.00%
52-Week High	$118.62
52-Week Low	$27.66
Volume	3.93M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-463.93M
Gross Margin	0.00%

Top Hedge Funds Holding PCVX

Maverick Capital holds 1.38M shares of PCVX, changed +1.74% as of Mar 31, 2026.
Farallon Capital holds 1.26M shares of PCVX, changed +25120.00% as of Mar 31, 2026.
Baupost Group holds 800.00K shares of PCVX, changed +0.00% as of Mar 31, 2026.
Orbimed Advisors holds 387.00K shares of PCVX, changed -51.38% as of Sep 30, 2024.
Duquesne Family holds 86.27K shares of PCVX, changed +100.78% as of Dec 31, 2024.

Latest PCVX News

Vaxcyte Raises $2.7B Cash, Completes Enrollment in Three Phase 3 VAX-31 Trials — May 6, 2026
Vaxcyte slides as lock-up expirations and insider sales rekindle supply worries — May 5, 2026
Vaxcyte rises as traders position ahead of May 6 Q1 earnings catalyst — May 4, 2026
Vaxcyte slips 3% as investors de-risk ahead of May 6 earnings — Apr 29, 2026
Vaxcyte slides as dilution overhang lingers after $632.5M raise, $500M ATM — Apr 24, 2026

Recent PCVX Insider Trades

Wassil Jim sold 2.25K (~$127.87K) on May 1, 2026.
Cowan Elvia sold 3.00K (~$180.00K) on Apr 7, 2026.
Wassil Jim sold 1.41K (~$82.09K) on Apr 1, 2026.

PCVX Analyst Consensus

8 analysts cover PCVX: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.43.

Common questions about PCVX

Who owns PCVX stock?: Hedge funds tracked by Rallies that own PCVX include Maverick Capital, Farallon Capital, Baupost Group, Orbimed Advisors, and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vaxcyte.
Does Rallies show 13F holders for PCVX?: Yes. Rallies tracks hedge fund and 13F ownership data for PCVX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PCVX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PCVX. It does not provide personalized investment advice.